Date Added: 20/03/2017

Date Updated: 20/03/2017

Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light (NB-UVB)

Specialties: Skin disease, burns and wound care

Technology Type: Drugs

Stage of development: Experimental - pilot or phase II

Stage of EAA: Prioritised for assessment

Description, patients and keywords:

Generalised vitiligo: adults; stable or slowly progressing; with 10-50% of total body surface involvement – first line; in combination with narrow-band ultraviolet B light (NB-UVB).

Afamelanotide (SCENESSE; [Nle4,D-Phe7]-alpha-MSH; CUV-1647; EPT-1647; melanotan I; melanotan) is a structural analogue of endogenous alpha-melanocyte-stimulating hormone (α-MSH), which is formulated as a bioresorbable implant. Afamelanotide acts as an agonist at the melanocortin 1 receptor, activating the synthesis and transport of eumelanin. Afamelanotide may facilitate repigmentation and proliferation of melanocytes from melanocyte reservoirs and is also believed to have antioxidant and immunomodulatory properties.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.